CY1115255T1 - Χρηση αναστολεων αποακετυλασης ιστονων για την φροντιδα philadelphia-αρνητικων μυελοπολλαπλασιαστικων συνδρομων - Google Patents

Χρηση αναστολεων αποακετυλασης ιστονων για την φροντιδα philadelphia-αρνητικων μυελοπολλαπλασιαστικων συνδρομων

Info

Publication number
CY1115255T1
CY1115255T1 CY20141100514T CY141100514T CY1115255T1 CY 1115255 T1 CY1115255 T1 CY 1115255T1 CY 20141100514 T CY20141100514 T CY 20141100514T CY 141100514 T CY141100514 T CY 141100514T CY 1115255 T1 CY1115255 T1 CY 1115255T1
Authority
CY
Cyprus
Prior art keywords
syndromes
philadelphia
negative
myeloperoplasty
histone deacetylase
Prior art date
Application number
CY20141100514T
Other languages
English (en)
Inventor
Tiziano Oldoni
Paolo Mascagni
Alessandro Rambaldi
Tiziano Barbui
Original Assignee
Italfarmaco Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco Spa filed Critical Italfarmaco Spa
Publication of CY1115255T1 publication Critical patent/CY1115255T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Περιγράφεται η χρήση ουσιών, οι οποίες είναι ικανές να αναστέλλουν ένα ή περισσότερα ένζυμα από την οικογένεια αποακετυλάσης ιστονών (αναστολείς αποακετυλάσης ιστονών) για την θεραπευτική αγωγή Philadelphia-αρνητικών μυελοπολλαπλασιαστικών συνδρόμων (αληθής πολυκυτταραιμία, ιδιοπαθής θρομβοκυτταραιμία ή ιδιοπαθής μυελοΐνωση). Η δοσολογία των προαναφερθεισών ουσιών είναι σημαντικά χαμηλότερη εν συγκρίσει προς την συνήθως χρησιμοποιούμενη κατά την φροντίδα άλλων συνδρόμων όγκου και είναι δυνατόν να ανέρχεται σε 10 έως 150 mg/ημέρα/ασθενή.
CY20141100514T 2008-09-29 2014-07-09 Χρηση αναστολεων αποακετυλασης ιστονων για την φροντιδα philadelphia-αρνητικων μυελοπολλαπλασιαστικων συνδρομων CY1115255T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2008A001720A IT1392908B1 (it) 2008-09-29 2008-09-29 Uso degli inibitori delle istone-deacetilasi per la cura di sindromi mieloproliferative philadelphia-negative
US19328308P 2008-11-13 2008-11-13
EP09783251.3A EP2344253B1 (en) 2008-09-29 2009-09-21 Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes

Publications (1)

Publication Number Publication Date
CY1115255T1 true CY1115255T1 (el) 2017-01-04

Family

ID=40810309

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100514T CY1115255T1 (el) 2008-09-29 2014-07-09 Χρηση αναστολεων αποακετυλασης ιστονων για την φροντιδα philadelphia-αρνητικων μυελοπολλαπλασιαστικων συνδρομων

Country Status (17)

Country Link
US (4) US20110294892A1 (el)
EP (1) EP2344253B1 (el)
JP (1) JP2012504112A (el)
KR (3) KR20170124640A (el)
CN (1) CN102164638A (el)
BR (1) BRPI0913699A2 (el)
CA (1) CA2738081C (el)
CY (1) CY1115255T1 (el)
DK (1) DK2344253T3 (el)
ES (1) ES2478827T3 (el)
HR (1) HRP20140499T1 (el)
IT (1) IT1392908B1 (el)
PL (1) PL2344253T3 (el)
PT (1) PT2344253E (el)
SI (1) SI2344253T1 (el)
SM (1) SMT201400087B (el)
WO (1) WO2010034693A1 (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8217079B2 (en) * 2010-03-26 2012-07-10 Italfarmaco Spa Method for treating Philadelphia-negative myeloproliferative syndromes
WO2015165975A1 (en) * 2014-04-29 2015-11-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating myeloid neoplasias
WO2018075959A1 (en) 2016-10-20 2018-04-26 Forma Therapeutics, Inc. Methods using hdac11 inhibitors
US10865328B2 (en) * 2017-02-20 2020-12-15 Dow Silicones Corporation Room-temperature-curable silicone composition and electric/electronic apparatus
US11535607B2 (en) 2018-04-20 2022-12-27 Valo Health, Inc. Isoindolines as HDAC inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
IT1283637B1 (it) 1996-05-14 1998-04-23 Italfarmaco Spa Composti ad attivita' antinfiammatoria ed immunosoppressiva
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
ITMI20030063A1 (it) * 2003-01-17 2004-07-18 Italfarmaco Spa Cloridrato monoidrato dell'estere (6-dietilamminometil-naftalen-2-il)metilico dell'acido (4-idrossicarbammoil-fenil)carbammico.
ITMI20030064A1 (it) * 2003-01-17 2004-07-18 Italfarmaco Spa Uso dei derivati dell'acido idrossamico per la preparazione
US7244751B2 (en) 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
WO2006063294A2 (en) * 2004-12-09 2006-06-15 Kalypsys, Inc. Novel inhibitors of histone deacetylase for the treatment of disease
US20070027184A1 (en) * 2005-07-29 2007-02-01 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
CN101426903A (zh) 2005-12-09 2009-05-06 麻省理工学院 基于细胞核形态鉴定并靶向肿瘤干细胞的方法
JP2010509370A (ja) * 2006-11-10 2010-03-25 シンダックス ファーマシューティカルズ，インク． 癌の治療用のＥＲα＋リガンドとヒストンデアセチラーゼ阻害剤との組み合わせ
WO2008082646A2 (en) * 2006-12-28 2008-07-10 The Johns Hopkins University Histone deacetylase inhibitors, combination therapies and methods of use

Also Published As

Publication number Publication date
SMT201400087B (it) 2014-09-08
EP2344253B1 (en) 2014-04-23
CA2738081A1 (en) 2010-04-01
PT2344253E (pt) 2014-07-16
KR20160096721A (ko) 2016-08-16
US20140039059A1 (en) 2014-02-06
WO2010034693A1 (en) 2010-04-01
DK2344253T3 (da) 2014-06-16
SI2344253T1 (sl) 2014-08-29
JP2012504112A (ja) 2012-02-16
PL2344253T3 (pl) 2014-09-30
EP2344253A1 (en) 2011-07-20
US9522127B2 (en) 2016-12-20
CA2738081C (en) 2017-11-07
US20210128512A1 (en) 2021-05-06
ES2478827T3 (es) 2014-07-23
BRPI0913699A2 (pt) 2017-06-13
HRP20140499T1 (hr) 2014-07-04
KR20110069075A (ko) 2011-06-22
CN102164638A (zh) 2011-08-24
US20170049740A1 (en) 2017-02-23
KR20170124640A (ko) 2017-11-10
US20110294892A1 (en) 2011-12-01
ITMI20081720A1 (it) 2010-03-30
IT1392908B1 (it) 2012-04-02

Similar Documents

Publication Publication Date Title
CY1122336T1 (el) Eνωσεις πυρρολιου ως αναστολεις πρωτεϊνικων κινασων εrκ και φαρμακευτικες συνθεσεις που περιεχουν αυτες τις ενωσεις
CY1124928T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
CY1117833T1 (el) Νεες συνθεσεις και μεθοδοι για την αγωγη του καρκινου
CY1125065T1 (el) Αναστολεις mcl-1
CY1115255T1 (el) Χρηση αναστολεων αποακετυλασης ιστονων για την φροντιδα philadelphia-αρνητικων μυελοπολλαπλασιαστικων συνδρομων
CY1121465T1 (el) Μεθοδοι και συνθεσεις για τη θεραπεια της φλεγμονωδους νοσου του εντερου
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
CY1117995T1 (el) Δευτεριωμενα παραγωγα κατεχολαμινης και φαρμακα που περιεχουν τις εν λογω ενωσεις
CY1118695T1 (el) Αναστολεις απομεθυλασων ιστονων
EA201891607A1 (ru) Axl-специфичные конъюгаты антитело-лекарственное средство для лечения злокачественных новообразований
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
CY1113651T1 (el) Αντιφλεγμονωδη σκευασματα
CY1114397T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν βακτηρια τα οποια μειωνουν οξαλικα
MX2009013729A (es) Imidazopirazinas como inhibidores de proteina quinasa.
ECSP099525A (es) Inhibidores de mek
CL2009001160A1 (es) Compuestos derivados de heterociclos nitrogenados fusionados y su composicion farmaceutica.
CY1112297T1 (el) Ετεροκυκλικοι αναστολεις της μεκ και μεθοδοι χρησης αυτων
ATE456571T1 (de) Proteasom-hemmer und verwendungsverfahren dafür
EA200801301A1 (ru) ИНГИБИТОРЫ АКТИВНОСТИ Akt
ECSP21038390A (es) Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr
CL2008001540A1 (es) Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
ATE423087T1 (de) Proteasome inhibitoren und deren verwendung
CY1110162T1 (el) Φαρμακοτεχνικη μορφη και μεθοδοι για την αγωγη της θρομβοκυτταραιμιας
CY1123240T1 (el) Αντισωμα αντι fgf23 και μια φαρμακευτικη συνθεση που το περιλαμβανει
ATE423114T1 (de) Aminocyclopropancarbonsäureamidderivate als bradykininantagonisten